Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as bcl-2 in benign epithelium and cancer of the prostate

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 47-52

  Ummanni, Ramesh ^a,b   Lehnigk, Ulrike ^a   Zimmermann, Uwe ^a   Woenckhaus, Christian ^a   Walther, Reinhard ^a   Giebel, Jürgen ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bcl 2; Benign prostate epithelium; Caspases; Immunohistochemistry; Prostate carcinoma

Indexed keywords

CASPASE; CASPASE 3; CASPASE 6; CASPASE 9; ENZYME ANTIBODY; INTERLEUKIN 1BETA CONVERTING ENZYME; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR CELL;

EID: 77955733458     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000008     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S and Wingo PAPA: Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1999.
2. Slee EA, Adrain C and Martin SJ: Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ 6: 1067-1074, 1999.
3. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, KagiDD, Hakem A, McCurrach M, Khoo W, Kaufman SA, SenaldiGG, Howard T, Lowe SW and Mak TW: Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806-819, 1998.
4. Harvey NL and Kumar S: The role of caspases in apoptosis. Adv Biochem Eng Biotechnol 62: 107-128, 1998.
5. Stegh AH and Peter ME: Apoptosis and caspases. Cardiol Clin 19: 13-29, 2001.
6. Nunez G, Benedict MA, Hu Y and Inohara N: Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-3245, 1998.
7. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687, 1998.
8. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
9. Thornberry NA, Bull HG, Calaycay JR, et al: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356: 768-774, 1992.
10. Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM and Salvesen GS: Caspase-9 can be activated without proteolytic processing. J Biol Chem 274: 8359-8362, 1999.
11. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, NewmeyerDD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9-dependent manner. J Cell Biol 144: 281-292, 1999.
12. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATPATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
13. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
14. Reed JC: Mechanisms of apoptosis. Am J Pathol 157: 1415-1430, 2000.
15. Winter RN, Kramer A, Borkowski A and Kyprianou N: Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res 61: 1227-1232, 2001.
16. Gleason DF and Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
17. Mellinger GT, Gleason D and Bailar J III: The histology and prognosis of prostatic cancer. J Urol 97: 331-337, 1967.
18. Woenckhaus C, Giebel J, Failing K, Fenic I, Dittberner T and Poetsch M: Expression of AP-2alpha, c-kit and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J Pathol 201: 278-287, 2003.
19. McNeal JE: Normal histology of the prostate. Am J Surg Pathol 12: 619-633, 1988.
20. McNeal JE: Regional morphology and pathology of the prostate. Am J Clin Pathol 49: 347-357, 1968.
21. McNeal JE: Origin and development of carcinoma in the prostate. Cancer 23: 24-34, 1969.
22. McNeal JE: Origin and evolution of benign prostatic enlargement. Invest Urol 15: 340-345, 1978.
23. Srodon M and Epstein JI: Central zone histology of the prostate: a mimicker of high-grade prostatic intraepithelial neoplasia. Hum Pathol 33: 518-523, 2002.
24. O'Neill AJ, Boran SA, O'Keane C, Coffey RN, Hegarty NJ, Hegarty P, Gaffney EF, Fitzpatrick JM and Watson RWRW: Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate 47: 183-188, 2001.
25. Sohn JH, Kim DH, Choi NG, Park YE and Ro JY: Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias. Histopathology 37: 555-560, 2000.
26. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR and GannPHPH: Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 6: 73, 2006.
27. Vakkala M, Paakko P and Soini Y: Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer 81: 592-599, 1999.
28. Kang JJ, Schaber MD, Srinivasula SM, Alnemri ES, LitwackGG, Hall DJ and Bjornsti MA: Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J Biol Chem 274: 3189-3198, 1999.
29. Allsopp TE, McLuckie J, Kerr LE, Macleod M, Sharkey J and Kelly JS: Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis. Cell Death Differ 7: 984-993, 2000.
30. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, PantazisPP, MillerLL, Liu E, Kirsch IR, Urasaki Y, Pommier Y and WeinsteinJN: Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis and molecular interaction mapping. Cancer Res 63: 1000-1011, 2003.
31. Lee SC, Chan J, Clement MV and Pervaiz S: Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics 6: 2386-2394, 2006.
32. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, ChungLW, Hsieh JT, Tu SM and Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
33. Tu H, Jacobs SC, Borkowski A and Kyprianou N: Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer 69: 357-363, 1996.
34. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE and Hamdy FC: Expression of Bcl-2, Bax and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 37: 223-229, 1998.